Title and Description Writing Quiz

Activating mutations in EGFR in non-small cell lung tumors exhibit sensitivity to targeted tyrosine kinase inhibitors.

Double mutants exhibit significant gain-of-function characteristics that account for their initial presence prior to drug selection and their quick selection as the single drug resistance mutation during therapy with gefitinib/erlotinib.

Adenocarcinomas developing in nonsmokers are characterized by mutations in the kinase domain of the EGF receptor.